Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Reported Earlier, Annexon Spotlights First-in-Class ANX005 Phase 3 Results For GBS And Launches 'Move GBS Forward' Initiative At AAN

Author: Benzinga Newsdesk | April 04, 2025 02:42am

Oral Plenary Presentation on Tuesday, April 8 Features Phase 3 Data for ANX005, the First Potential Targeted Therapy for GBS, Showing Rapid and Durable Benefit Across Clinical Measures and Time Points

Educational Symposium Focuses on Advancing GBS Care and Role of Classical Complement Pathway

New Disease Education Campaign "Move GBS Forward" Draws Attention to Life-altering Physical and Mental Impact of GBS

Posted In: ANNX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist